Frontotemporal Dementia

Neurology
7
Pipeline Programs
8
Companies
17
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
4
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
1100%
+ 8 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Alector
AlectorCA - South SF
2 programs
1
1
AL001Phase 31 trial
AL001Phase 21 trial
Active Trials
NCT03987295Completed33Est. Jun 2024
NCT04374136Terminated119Est. Jan 2026
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
galantamine hydrobromidePhase 25 trials
Active Trials
NCT00297362Completed344Est. Oct 2005
NCT00216515Completed102Est. Nov 2005
NCT00216593Completed415Est. Mar 2008
+2 more trials
Takeda
TakedaTOKYO, Japan
1 program
1
DNL593Phase 1/21 trial
Active Trials
NCT05262023Active Not Recruiting85Est. Nov 2028
Denali Therapeutics
Denali TherapeuticsCA - South SF
1 program
1
DNL593Phase 1/2
AviadoBio
AviadoBioUK - London
1 program
1
Intrathalamic AAV.PGRN administrationPhase 1/2Gene Therapy1 trial
Active Trials
NCT06064890RecruitingEst. Mar 2030
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY3884963Phase 1/21 trial
Active Trials
NCT04408625Active Not Recruiting35Est. Nov 2029
Biogen
BiogenCAMBRIDGE, MA
1 program
AssessmentsN/A3 trials
Active Trials
NCT03681015Completed132Est. Mar 2022
NCT03088956Completed47Est. Sep 2019
NCT04926129Completed201Est. Dec 2022
C
CENTOGENEGermany - Rostock
1 program
Genetic ScreeningN/A1 trial
Active Trials
NCT05075187Unknown4,500Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Johnson & Johnsongalantamine hydrobromide
AlectorAL001
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine hydrobromide
AlectorAL001
Johnson & Johnsongalantamine hydrobromide
AviadoBioIntrathalamic AAV.PGRN administration
TakedaDNL593
Eli Lilly and CompanyLY3884963
CENTOGENEGenetic Screening
BiogenAssessments
BiogenAssessments

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 9,069 patients across 17 trials

NCT00216515Johnson & Johnsongalantamine hydrobromide

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Start: Mar 2004Est. completion: Nov 2005102 patients
Phase 4Completed
NCT04374136AlectorAL001

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Start: Jul 2020Est. completion: Jan 2026119 patients
Phase 3Terminated
NCT00216593Johnson & Johnsongalantamine hydrobromide

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Start: Dec 2003Est. completion: Mar 2008415 patients
Phase 3Completed
NCT00240695Johnson & Johnsongalantamine hydrobromide

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Start: May 2003Est. completion: May 2004724 patients
Phase 3Completed
NCT00216502Johnson & Johnsongalantamine hydrobromide

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Start: Aug 2001Est. completion: Nov 2005254 patients
Phase 3Completed
NCT00236431Johnson & Johnsongalantamine hydrobromide

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Start: May 2001Est. completion: Dec 20031,063 patients
Phase 3Completed
NCT00236574Johnson & Johnsongalantamine hydrobromide

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Start: May 2001Est. completion: Nov 2003974 patients
Phase 3Completed
NCT03987295AlectorAL001

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Start: Sep 2019Est. completion: Jun 202433 patients
Phase 2Completed
NCT00416169Johnson & Johnsongalantamine hydrobromide

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

Start: May 2003Est. completion: Jul 200441 patients
Phase 2Completed
NCT06064890AviadoBioIntrathalamic AAV.PGRN administration

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Start: Aug 2023Est. completion: Mar 2030
Phase 1/2Recruiting
NCT05262023TakedaDNL593

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Start: Feb 2022Est. completion: Nov 202885 patients
Phase 1/2Active Not Recruiting
NCT04408625Eli Lilly and CompanyLY3884963

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Start: Nov 2020Est. completion: Nov 202935 patients
Phase 1/2Active Not Recruiting
NCT05075187CENTOGENEGenetic Screening

Epidemiological Study in FRONtoTemporal Dementia

Start: Sep 2021Est. completion: Sep 20244,500 patients
N/AUnknown
NCT03681015BiogenAssessments

Wearable Assessments in the Clinic and Home in PD

Start: Apr 2019Est. completion: Mar 2022132 patients
N/ACompleted
NCT03088956BiogenAssessments

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

Start: Jan 2018Est. completion: Sep 201947 patients
N/ACompleted
NCT04926129BiogenAssessments

Natural History of the Progression of X-Linked Retinitis Pigmentosa

Start: Sep 2017Est. completion: Dec 2022201 patients
N/ACompleted
NCT00297362Johnson & Johnsongalantamine hydrobromide

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Start: Jun 2004Est. completion: Oct 2005344 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
8h ago

Director of Finance

CoMind
London, UK
8h ago

Electronics Engineering Manager

CoMind
London, UK
8h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 9,069 patients
8 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)